By Suherman Candra Maholtra 
A comprehensive study conducted by researchers at Vanderbilt University Medical Center and the Department of Veterans Affairs (VA) has provided the most robust evidence to date regarding the efficacy of nicotinamide, a form of vitamin B3, in preventing nonmelanoma skin cancers. By analyzing a massive cohort of over 33,000 veterans, the research team demonstrated that early intervention with this over-the-counter supplement can reduce the risk of developing new skin cancers by as much as 54% in specific patient populations. These findings, published in a recent medical journal, represent a potential turning point in dermatological preventative care, suggesting that the timing of treatment may be just as critical as the treatment itself.
The Evolution of Nicotinamide in Preventative Dermatology
The medical community’s interest in nicotinamide as a chemopreventive agent for skin cancer began in earnest nearly a decade ago. In 2015, a landmark clinical trial known as the ONTRAC (Oral Nicotinamide to Reduce Actinic Cancer) study, conducted in Australia, first suggested that vitamin B3 could play a role in skin health. That trial involved 386 participants and found that 500 milligrams of nicotinamide taken twice daily reduced the incidence of new nonmelanoma skin cancers by 23% over a 12-month period.
Despite the promising results of the ONTRAC trial, dermatologists faced a significant hurdle in implementing broad clinical guidelines: the study size was relatively small. Furthermore, because nicotinamide is an inexpensive, over-the-counter supplement, tracking its use in the general population proved difficult. Unlike prescription medications, which leave a clear paper trail in insurance claims and pharmacy records, supplements are often purchased without professional supervision, making large-scale observational studies nearly impossible in a standard healthcare setting.
To bridge this gap in evidence, the research team led by Lee Wheless, MD, PhD, assistant professor of Dermatology and Medicine at Vanderbilt University Medical Center, turned to the Veterans Affairs Corporate Data Warehouse. The VA system provided a unique opportunity because, unlike most private healthcare providers, it includes nicotinamide on its official formulary. This allowed researchers to access verified medical records indicating exactly when patients were prescribed the supplement and for what duration, providing a dataset of unprecedented scale.
Methodology and the Scale of the VA Study
The study utilized a retrospective cohort design, reviewing the outcomes of 33,833 veterans. This population is particularly relevant for skin cancer research, as veterans often have high levels of cumulative sun exposure from their time in service, placing them at an elevated risk for basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (SCC).
The researchers identified 12,287 patients who had been prescribed 500 milligrams of nicotinamide twice daily for at least 30 days. These individuals were compared against a control group of 21,479 veterans who did not receive the supplement. The team then meticulously tracked each patient’s subsequent diagnoses of BCC and SCC, the two most common forms of nonmelanoma skin cancer.
The sheer volume of data allowed the researchers to look beyond a simple "yes or no" answer regarding the supplement’s efficacy. They were able to categorize patients based on their prior history of skin cancer, the timing of their nicotinamide initiation, and their overall health status, including whether they were immunocompromised.
Statistical Breakdown: A Dramatic Shift in Risk Reduction
The results of the study revealed a clear, albeit nuanced, benefit to nicotinamide supplementation. Across the entire study population of more than 33,000 individuals, there was a 14% overall decrease in the risk of developing a new skin cancer diagnosis. While statistically significant, this number only tells part of the story.
The most striking finding emerged when the researchers analyzed the timing of when patients began their nicotinamide regimen. For veterans who started taking the supplement immediately after their very first skin cancer diagnosis, the risk of developing a subsequent cancer plummeted by 54%. This suggests a critical "window of opportunity" for preventative intervention.
However, the data also indicated a diminishing return for patients who waited longer to begin treatment. For those who had already developed multiple skin cancers before starting nicotinamide, the preventative benefit was notably lower. This suggests that while nicotinamide can help repair cellular damage and prevent new mutations, it may be less effective at reversing the cumulative damage present in skin that has already transitioned into a state of frequent malignancy.
In terms of cancer types, the effect was most pronounced for cutaneous squamous cell carcinoma (SCC). SCC is known for its potential to grow deeply into the skin and, in some cases, spread to other parts of the body. The ability of a simple vitamin supplement to significantly curtail the development of these lesions represents a major victory for low-cost, high-impact preventative medicine.
The Biological Mechanism: How Vitamin B3 Protects the Skin
To understand why nicotinamide is effective, it is necessary to look at the cellular impact of ultraviolet (UV) radiation. When skin is exposed to UV light, it causes DNA damage and depletes cellular energy in the form of adenosine triphosphate (ATP). This energy depletion hampers the skin’s natural ability to repair DNA mutations, leading to the uncontrolled cell growth that characterizes cancer.
Nicotinamide is a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme essential for ATP production. By boosting NAD+ levels, nicotinamide helps the skin maintain the energy levels required for DNA repair enzymes to function effectively. Furthermore, nicotinamide has been shown to reduce the immunosuppressive effects of UV radiation on the skin, allowing the body’s local immune system to better identify and eliminate precancerous cells before they become tumors.
Challenges in Immunocompromised Populations
The study also delved into a particularly vulnerable subgroup: patients who are immunocompromised due to solid organ transplants. These individuals are at a vastly higher risk for skin cancer—sometimes up to 100 times the risk of the general population—due to the immunosuppressive drugs required to prevent organ rejection.
In this group of ,1334 patients, the overall risk reduction provided by nicotinamide did not reach statistical significance. While there were observed trends toward fewer cases of squamous cell carcinoma among those who started the supplement early, the overwhelming nature of their skin cancer risk appeared to blunt the supplement’s protective effects.
Dr. Wheless noted that while the results in the transplant group were not as definitive as in the general veteran population, the findings still provide a baseline for future research into how preventative strategies might be tailored for high-risk, immunocompromised patients.
Expert Reactions and the Shift in Clinical Strategy
The implications of this study are expected to resonate through dermatology clinics nationwide. Historically, nicotinamide was often reserved as a "last resort" for patients who were already "frequent fliers" in the dermatology office—those developing several skin cancers per year.
"There are no guidelines for when to start treatment with nicotinamide for skin cancer prevention in the general population," explained Dr. Lee Wheless. "These results would really shift our practice from starting it once patients have developed numerous skin cancers to starting it earlier."
The study suggests that the current reactive approach may be missing the most effective period for intervention. By shifting the clinical focus toward early prevention—perhaps even after the very first diagnosis of a nonmelanoma skin cancer—physicians may be able to significantly alter the disease trajectory for millions of patients.
However, Dr. Wheless also urged a measured approach, noting that the medical community still needs to refine its ability to identify which patients will benefit most. "We still need to do a better job of identifying who will actually benefit, as roughly only half of patients will develop multiple skin cancers," he stated. Over-prescribing supplements to those at low risk of recurrence could lead to unnecessary healthcare costs and patient burden.
Broader Impact on Public Health and Healthcare Costs
Nonmelanoma skin cancer is the most common form of cancer in the United States, with millions of new cases diagnosed each year. While BCC and SCC are rarely fatal if caught early, the cumulative cost of treating these lesions is staggering. The surgical procedures, follow-up appointments, and pathology costs associated with managing skin cancer place a heavy burden on both the VA healthcare system and private insurers.
If nicotinamide can reduce the incidence of new cases by 14% to 54%, the potential cost savings are immense. As an over-the-counter supplement, nicotinamide is incredibly inexpensive, often costing only pennies per dose. When compared to the thousands of dollars required for a single Mohs micrographic surgery (a common treatment for skin cancer), the economic argument for widespread, early supplementation in at-risk populations becomes compelling.
Furthermore, the study highlights the importance of large-scale data systems like the VA Corporate Data Warehouse in advancing medical knowledge. Without the ability to track thousands of patients over several years in a controlled environment, the nuances of this "early intervention" benefit might never have been uncovered.
Conclusion and Future Directions
The Vanderbilt and VA study provides a clear mandate for the dermatological community to re-evaluate its preventative protocols. By demonstrating that nicotinamide is most effective when used early in the progression of skin cancer history, the research paves the way for new clinical guidelines that emphasize proactive care.
Future research will likely focus on refining the patient selection process. Scientists may look for genetic markers or specific clinical profiles that predict a high response to nicotinamide. Additionally, more work is needed to determine if higher doses or combinations with other preventative agents could improve outcomes for the immunocompromised population.
For now, the message for patients and providers is clear: in the fight against skin cancer, timing is everything. Starting nicotinamide sooner rather than later could be the key to significantly reducing the long-term burden of this prevalent disease. The study’s success was made possible through the collaboration of a dedicated team at Vanderbilt, including Katyln Knox, Rachel Weiss, Siwei Zhang, PhD, Lydia Yao, MS, Yaomin Xu, PhD, and Kyle Maas, with support from a Department of Veterans Affairs grant.
